Strong political will in Germany for EU HTA harmonisation
by Catherine Featherston
BERLIN, Sep 30, 2016 (APM) - Now that the pharma dialogue has finished and a new German drugs law is expected to be passed, the 'main' topic for the health ministry is European cooperation on health technology assessment (HTA), a German federal HTA official has said.
Germany has 'much more' political interest now in seeing the successful outcome of the third - and final - phase of the EU's attempt to promote collaboration of HTA bodies in Europe, said Thomas Mueller, medicines department head of Germany's higher assessment body, the G-BA.
Read more:
www.apmhealtheurope.com
International reference pricing should remain limited - German industry
by Hélène Mauduit
BERLIN, Oct 4, 2016 (APM) - Comparing prices in different European countries is complex and should be carried out by payers and pricing authorities under specific conditions, the secretary general of the European confederation of pharmaceutical entrepreneurs (Eucope) has said.
The impact of international reference pricing should be more widely debated, Alexander Natz said at the Forum-Institut für management conference on 'national HTA assessment and value assessment in Europe' on Friday in Berlin.
Read more:
www.apmhealtheurope.com
France accelerating pace of health technology assessments for new drugs
by Catherine Featherston
BERLIN, Oct 4, 2016 (APM) - After years of falling behind its 90-day limit for issuing health technology assessments (HTA) for new drugs, France has consolidated the average at 100 days, according to the president of the Transparency Commission (CT) of French HTA agency HAS.
The problem used to be much worse, said Loic Guillevin at the Forum-Institut für management conference 'National HTA Assessment and Value Assessment in Europe', but the CT is committed to shortening the time between a pharma's filing of a dossier and the commission's issuing of its opinion to the health ministry.
Read more:
www.apmhealtheurope.com
Long-term EU level HTA to focus on data sharing
by Catherine Featherston
BERLIN, Oct 5, 2016 (APM) - The legal framework for long-term European level cooperation on health technology assessment (HTA) is likely to regulate how data is collected, shared, used and to create common tools and IT platforms for data assessment, said Francois Meyer, international affairs director of French HTA agency HAS.
The idea behind coordination is to produce significant savings through one joint HTA report for new drugs, or to at least streamline elements of HTA, said Meyer, speaking at the Forum-Institut für management conference 'National HTA Assessment and Value Assessment in Europe' in Berlin.
Read more:
www.apmhealtheurope.com
Move to the top
